An immunoinhibitory receptor, Allergin-1 is the target molecule for treatment of allergic asthma

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K15319
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: University of Tsukuba
• Principal Investigator: TAHARA Satoko 筑波大学, 生命領域学際研究センター, 講師 (20360589)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 喘息 / アラジン－１

Outline of Final Research Achievements

Allergin-1 is an inhibitory immunoglobulin-like receptor bearing immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic region. Allergin-1 inhibits house dust mite-induced serum IgE elevation, airway eosinophilia, and airway hyperreactivity (AHR), therefore, Allergin-1 may be a target molecule for treatment of allergic asthma. In this proposal, a phospholipid liposome was used to treat the HDM-induced allergic asthma. Because, one of the phospholipid has an ability to bind to Allergin-1. However, in the HDM-induced asthma model, not only Allergin-1-binding phospholipid, but also phosphatidylcholine, which does not bind to Allergin-1 inhibited the AHR.

Free Research Field

免疫学